GILEAD SCIENCES, INC. (GILD) Operating Margin
- Operating margin · 12 months: Value -8.20%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -8.20% | Operating income / revenue. Period ending 2026-06-30. $-2.50B ÷ $30.46B × 100 ≈ -8.20% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -2.50B USD | Operating Income (Loss) |
| Revenue | 30.46B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 6.22B USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 6.52B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-2.50B | $30.46B | $6.22B | (m) | $6.52B | -8.20% |
| 2026-03-31 | $10.37B | $29.74B | $6.14B | (m) | $5.97B | 34.88% |
| 2025-12-31 | $10.02B | $29.44B | $6.23B | (m) | $5.77B | 34.04% |
| 2025-09-30 | $10.49B | $29.09B | $6.19B | (m) | $5.89B | 36.06% |
| 2025-06-30 | $8.05B | $28.86B | $6.20B | (m) | $5.96B | 27.89% |
| 2025-03-31 | $8.22B | $28.73B | $6.24B | (m) | $5.97B | 28.61% |
| 2024-12-31 | $1.66B | $28.75B | $6.25B | (m) | $6.09B | 5.78% |
| 2024-09-30 | $822.00M | $28.30B | $6.76B | (m) | $5.79B | 2.90% |
| 2024-06-30 | $2.56B | $27.80B | $6.75B | (m) | $5.67B | 9.20% |
| 2024-03-31 | $1.58B | $27.45B | $6.65B | (m) | $6.15B | 5.75% |
| 2023-12-31 | $7.61B | $27.12B | $6.50B | (m) | $6.09B | 28.05% |
| 2023-09-30 | $8.26B | $27.39B | $5.80B | (m) | $6.50B | 30.16% |
| 2023-06-30 | $8.47B | $27.38B | $5.63B | (m) | $6.40B | 30.95% |
| 2023-03-31 | $8.84B | $27.04B | $5.63B | (m) | $5.91B | 32.68% |
| 2022-12-31 | $7.33B | $27.28B | $5.66B | (m) | $5.67B | 26.87% |
| 2022-09-30 | $6.00B | $27.14B | $6.89B | (m) | $5.30B | 22.12% |
| 2022-06-30 | $7.01B | $27.52B | $6.72B | (m) | $5.28B | 25.47% |
| 2022-03-31 | $7.22B | $27.47B | $6.66B | (m) | $5.27B | 26.30% |
| 2021-12-31 | $9.92B | $27.30B | $6.60B | (m) | $5.25B | 36.32% |
| 2021-09-30 | $11.63B | $27.48B | $5.37B | (m) | $5.33B | 42.31% |
| 2021-06-30 | $9.79B | $26.64B | $5.29B | (m) | $5.24B | 36.74% |
| 2021-03-31 | $4.56B | $25.56B | $4.96B | (m) | $5.13B | 17.83% |
| 2020-12-31 | $4.07B | $24.69B | $4.57B | (m) | $5.15B | 16.49% |
| 2020-09-30 | $2.51B | $23.15B | $4.86B | (m) | $4.63B | 10.86% |
| 2020-06-30 | $-961.00M | $22.17B | $4.75B | (m) | $4.57B | -4.33% |
| 2020-03-31 | $4.45B | $22.72B | $4.69B | $9.15B | $4.43B | 19.60% |
| 2019-12-31 | $4.29B | $22.45B | $4.67B | $9.11B | $4.38B | 19.10% |
| 2019-09-30 | $4.34B | $22.36B | $4.56B | $9.16B | $4.31B | 19.40% |
| 2019-06-30 | $8.43B | $22.36B | $4.61B | $5.11B | $4.20B | 37.72% |
| 2019-03-31 | $8.28B | $22.32B | $4.81B | $5.14B | $4.09B | 37.11% |
| 2018-12-31 | $8.20B | $22.13B | $4.85B | $5.02B | $4.06B | 37.06% |
| 2018-09-30 | $9.35B | $22.28B | (m) | $4.22B | $4.18B | 41.95% |
| 2018-06-30 | $10.54B | $23.20B | (m) | $4.07B | $4.11B | 45.42% |
| 2018-03-31 | $12.51B | $24.69B | (m) | $3.74B | $4.03B | 50.67% |
| 2017-12-31 | $14.12B | $26.11B | (m) | $3.73B | $3.88B | 54.10% |
| 2017-09-30 | $15.88B | $27.48B | (m) | $3.79B | $3.62B | 57.78% |
| 2017-06-30 | $16.46B | $28.47B | (m) | $4.14B | $3.57B | 57.84% |
| 2017-03-31 | $16.75B | $29.10B | (m) | $4.76B | $3.56B | 57.55% |
| 2016-12-31 | $17.63B | $30.39B | (m) | $5.10B | $3.40B | 58.02% |
| 2016-09-30 | $19.21B | $31.58B | (m) | $4.65B | $3.47B | 60.83% |
| 2016-06-30 | $20.39B | $32.37B | (m) | $4.25B | $3.54B | 63.00% |
| 2016-03-31 | $21.47B | $32.84B | (m) | $3.58B | $3.47B | 65.39% |
| 2015-12-31 | $22.19B | $32.64B | (m) | $3.01B | $3.43B | 68.00% |
| 2015-09-30 | $20.90B | $31.45B | (m) | $3.30B | $3.24B | 66.47% |
| 2015-06-30 | $18.80B | $29.19B | (m) | $3.19B | $3.28B | 64.39% |
| 2015-03-31 | $17.59B | $27.48B | (m) | $2.96B | $3.08B | 64.01% |
| 2014-12-31 | $15.27B | $24.89B | (m) | $2.85B | $2.98B | 61.33% |
| 2014-09-30 | $12.13B | $20.70B | (m) | $2.36B | $2.62B | 58.62% |
| 2014-06-30 | $9.80B | $17.44B | (m) | $2.28B | $2.08B | 56.21% |
| 2014-03-31 | $6.54B | $13.67B | (m) | $2.22B | $1.87B | 47.86% |
| 2013-12-31 | $4.52B | $11.20B | (m) | $2.12B | $1.70B | 40.39% |
| 2013-09-30 | $4.43B | $10.67B | (m) | (m) | $1.55B | 41.55% |
| 2013-06-30 | $4.33B | $10.31B | (m) | (m) | $1.46B | 41.98% |
| 2013-03-31 | $4.24B | $9.95B | (m) | (m) | $1.39B | 42.56% |
| 2012-12-31 | $4.01B | $9.70B | (m) | (m) | $1.46B | 41.33% |
| 2012-09-30 | $3.77B | $9.31B | (m) | (m) | $1.44B | 40.48% |
| 2012-06-30 | $3.73B | $9.01B | (m) | (m) | $1.42B | 41.40% |
| 2012-03-31 | $3.69B | $8.74B | (m) | (m) | $1.39B | 42.19% |
| 2011-12-31 | $3.79B | $8.39B | (m) | (m) | $1.24B | 45.20% |
| 2011-09-30 | $3.75B | $8.18B | (m) | (m) | $1.18B | 45.84% |
| 2011-06-30 | $3.73B | $8.00B | (m) | (m) | $1.13B | 46.59% |
| 2011-03-31 | $3.70B | $7.79B | (m) | (m) | $1.07B | 47.54% |
| 2010-12-31 | $3.96B | $7.95B | (m) | (m) | $1.04B | 49.84% |
| 2010-09-30 | $4.20B | $7.98B | (m) | (m) | $1.02B | 52.59% |
| 2010-06-30 | $4.11B | $7.85B | (m) | (m) | $994.95M | 52.42% |
| 2010-03-31 | $3.88B | $7.57B | (m) | (m) | $1.01B | 51.30% |
| 2009-12-31 | $3.53B | $7.01B | (m) | (m) | $946.69M | 50.34% |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $2.68B | $5.34B | (m) | (m) | $797.34M | 50.20% |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | $2.16B | $4.23B | (m) | (m) | $705.74M | 51.17% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |